IPP Bureau
Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis
By IPP Bureau - October 09, 2025
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka
By IPP Bureau - October 09, 2025
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform
By IPP Bureau - October 09, 2025
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Briefs: Panacea Biotec and Shukra Pharmaceuticals
By IPP Bureau - October 09, 2025
Panacea Biotec receives acceptance from CMSS for supply of bOPV
RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia
By IPP Bureau - October 08, 2025
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Terumo India launches FineCross M3 micro-guide catheter
By IPP Bureau - October 08, 2025
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions launch Integrated CMC Partnership to accelerate drug development
By IPP Bureau - October 08, 2025
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
VectorBuilder Redefines Plasmid Standards with miniVec
By IPP Bureau - October 08, 2025
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction
By IPP Bureau - October 08, 2025
New study presents a human-relevant stress model for assessing potential therapeutics
Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra
By IPP Bureau - October 08, 2025
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Lupin to build $250 million manufacturing facility in Florida
By IPP Bureau - October 08, 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Pharmanovia appoints Stephan Eder as CEO
By IPP Bureau - October 07, 2025
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Alembic and Amlan launch feed additive solutions for poultry
By IPP Bureau - October 07, 2025
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets
By IPP Bureau - October 07, 2025
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Briefs: Shilpa Medicare and Medico Remedies
By IPP Bureau - October 07, 2025
Medico Remedies receives order worth US$ 1,781,000
